FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Ascentage’s Venclexta challenge looks wildly optimistic
A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.
AACR 2024 preview – Lag3, TIGIT and more
BeiGene has a strong presence at this year’s AACR, which features several notable duels.
Revolution pushes home its pan-KRAS advantage
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
The new normal in US oncology approvals
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
Mesothelin lives on
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
KRAS and conjugates remain hot
The latest clinical study listings reveal KRAS-targeting projects, ADCs and others starting phase 1.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
